Cargando…
非小细胞肺癌EGFR突变的分子影像学在体检测
An ever increasing number of drugs directed as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell lung cancer (NSCLC) therapy, and many large scales of studies show that only people with EGFR-sensitive mutation can benefit from these drugs...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973363/ https://www.ncbi.nlm.nih.gov/pubmed/28641700 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.08 |